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bstract
he resources invested in research do not guarantee an immediate practical application. Companies and government increasingly seek mechanisms
or prioritizing R&D projects appropriately when resources are insufficient. This study’s objective was to develop and present a methodology
sed to evaluate the portfolio of research and help choosing the best investments in research. This methodology was applied at the Butanta
nstitute, in Brazil, an organization responsible for researching and developing, among other medicines, vaccines and other chemicals, Onco BCG,
 medication for the treatment of bladder cancer. In the article, we present and analyze the methodology used at Butanta Institute. Conclusions
how that literature on R&D portfolio management advises the use of risk and return criteria, when choosing among projects. In the case study of
utanta, the methodology of choice was based more on the customer’s perspective.
 2016 Departamento de Administrac¸a˜o, Faculdade de Economia, Administrac¸a˜o e Contabilidade da Universidade de Sa˜o Paulo – FEA/USP.
ublished by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Choosing the best portfolio of projects of research and devel-
pment (R&D) is an important discussion when dealing with
echnological strategy. One reason for that is the substantial
mount of investment on research and which not always can be
eflected into results. Another issue is the cash flow dilemma:
xpenses in research and development today can bring results
n a long term perspective. This paper presents a methodology
or evaluation of the R&D portfolio at a government institute,
n Brazil, which is responsible for development of many medi-
ations.
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tudies under technological strategy, named portfolio selection
rocess (Blanes i Vidal & Möller, 2016). In this field, past studies
ave come up with methodologies that support decision mak-
rs in choosing how they will invest their financial resources,
iven the amplitude of R&D projects available. Many of these
ethods are built on complex methods such as the fuzzy logic
Bhattacharyya, 2015). However, these methods do not fit all
ypes of companies or the problems they face; one of these cases
here there is a call for more adaptive models is the case of
onprofit organizations (Jeng & Huang, 2015).
One of the nonprofit sectors that demand such studies is the
ealth Programs, as the results of the research directly impacts
he population well-being. Avoiding primary research can pre-
ent the discovery of cure for many diseases.
When we look for answers for the problem of choosing
he best R&D portfolio of projects, part of the literature show
ethodologies of evaluation of R&D portfolio based on therade-off between risk and return. Those studies consider the
nancial impacts as the most important criteria for decision.
his fact is expected, considering that the most part of the studies
istrac¸a˜o e Contabilidade da Universidade de Sa˜o Paulo – FEA/USP. Published
p://creativecommons.org/licenses/by/4.0/).
2 dmin
f
m
p
b
t
s
(
i
f
d
B
f
S
a
f
t
o
f
n
m
a
h
c
A
i
s
r
c
t
g
a
i
t
t
m
a
s
i
o
t
o
a
s
C
b
b
p
u
p
o
t
P
p
p
b
a
b
a
c
t
o
e
o
a
t
e
fi
r
C
o
i
a
r
i
a
e
a
t
t
s
r
c
g
c
e
d
m
T
i
o
e
s
o
m
w
l
D00 E.P. Vasconcellos et al. / RAI Revista de A
ocus on private companies. When it comes to health develop-
ents, the search of the cure of important diseases depends on
rojects that have high costs and also high risks. In the trade-off
etween risk and return, used as the only criteria for the selection,
hese projects could be among the least preferable ones. This is
pecifically true for the case of non-governmental organizations
Lacerda, 2015). The choice of less risky projects could make
mpossible the cure of important diseases, in the future.
This study objectives to develop and apply a methodology
or choosing the best portfolio of R&D when it comes to the
evelopment of one of the products of Butanta Institute: the Onco
CG vaccine. This vaccine is one of the medications designed
or the treatment of bladder cancer.
Butanta Institute is a governmental agency affiliated with the
ao Paulo State Health Department, in Brazil. It carries out many
ctivities aimed at preventing and correcting health problems
aced by the population of the state. Among these activities,
here are scientific and technological research projects devel-
ped by state-owned research institutions. Such research is very
requently out of touch with the Department of Health’s priority
eeds. This happens partly for lack of awareness of the Depart-
ent’s needs, which are not taken into consideration. There
re evidently other reasons for the mismatch. Martin (1994)
ighlights the importance of investing in innovations geared to
learly identified needs so as to increase the chances of success.
lthough his observation relates to private-sector companies, it
s equally applicable to the public sector. Another possible rea-
on for the divergence between strategic research needs and the
esearch that is really developed is that, in the Butanta Institute
ase, the research is primarily funded and developed by scien-
ists with academic scholarships provided by the government;
iven that, the ones who decide what subject will be researched
re the scientists themselves, according to their own research
nterests. The demand for research comes not necessarily from
he Butanta Institute or its product engineers, but it comes from
he researchers themselves.
The study described here entailed the development of a
ethodology for evaluating R&D project portfolios and partial
pplication to test its effectiveness. The experiment demon-
trated the method’s considerable potential as an ancillary
nstrument for evaluating an R&D portfolio. To test the method-
logy we chose BCG immunotherapy, a medication used in the
reatment of bladder cancer. If these needs are identified, part
f the research effort can be directed toward supporting them so
s to increase the general public’s satisfaction with the health
ervices provided by the public sector, at a lower cost to society.
onceptual  framework
Procedures to manage portfolios of technology projects have
een developed and applied by private enterprise as part of a
roader process known as Technology Management. The pur-
ose of Technology Management is to ensure that technology is
sed to leverage competitiveness by creating new products and
rocesses, enhancing existing ones, cutting costs, and devel-
ping patents that guarantee a temporary monopoly. Among
he tools of Technology Management is Strategic Technology
t
a
a
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lanning, which comprises several stages including project
ortfolio management. These concepts can also be used by
ublic-sector entities. In this case the pursuit of profit is replaced
y the desire to create quality products and services for society
t a low cost and on a timely basis. Once priority needs have
een identified, the existing project portfolio can be evaluated
nd new projects identified. Existing project selection methods
an then be applied.
Technology is an ancillary instrument for the implementa-
ion of such programs. It boosts their performance in terms
f quality and cost savings, so that healthcare services can be
xtended to more people for the same cost. Hence the importance
f establishing R&D priorities.
It must be stressed out, however, that part of the resources
llocated to research should be kept available for projects geared
o the advancement of science. This is especially valid for gov-
rnmental research institutions, although some private-sector
rms invest a small proportion of available funds in scientific
esearch.
ontext  of  project  portfolio  decisions
Project portfolio management should be aligned with the
rganization’s technology strategy, which in turn needs to be
ntegrated with corporate strategy. Much of the specialist liter-
ture on strategic management indicates that one of the main
easons for which firms develop a strategic plan is the need to
dentify the future environment in which the firm intends to oper-
te. This is done by analyzing a series of variables in order to
stablish basic guidelines to be followed by all members with
 minimum of stability. There are many strategy concepts and
ypologies, each one advocated by authors who follow one of
he many schools of thought on the subject that have emerged
o far. This paper focuses on the approaches considered most
elevant to the object of study.
On the method of strategy formulation, Mintzberg (1998)
lassifies strategies into: emerging strategies, deliberate strate-
ies, and deliberately emerging strategies. For him strategies
an either take shape or be formulated. A given strategy may
merge as a response to an evolving situation or be introduced
eliberately through a process of formulation followed by imple-
entation (Oliveira, Salazar, Crêspo, Costa, & Kovacs, 2015).
hus strategies are termed deliberate when constant planning
ntentions have been fully satisfied. Emerging strategies, on the
ther hand, derive from actions undertaken by the firm but not
xplicitly planned as such.
Because emerging strategies are comparatively flexible, they
timulate learning but hamper control, since actions are taken
ne at a time as the need arises. This type of strategy seems
ost suited to situations of technological paradigm change, in
hich a “window of opportunity” must be used quickly to estab-
ish a competitive advantage (which also may or may not last).
eliberate strategies, on the other hand, are intended to establishhe best form of control but cannot accurately foresee the future
nd keep all the factors involved within expecting situations so
s to achieve their goals (Neis & Pereira, 2016). As a trade-
ff between the two types of strategies Mintzberg proposes a
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eliberately emerging strategy, also known as process strategy.
n this case, “management controls the strategy formulation pro-
ess – focusing on designing structure, staffing, procedures and
o on – but leaves content proper to others”.
In the specific case of technological innovation, Roussel,
aad, and Erickson (1991) stress the importance of integrating
echnology needs identification with corporate strategy. Apply-
ng this concept to the government sector, the Department of
ealth should clearly define its strategic priorities in terms of
hat products and services to make available to what segments
f the population. The relationship between strategy and tech-
ology management is discussed in depth by Brockhoff (1998).
Bignetti (2001) cites Ansoff (1965) and Andrews (1971) to
rgue that classic studies of innovation generally refer to orga-
izations which interact with relatively stable environments and
re characterized by relatively long product and technology life-
ycles. This is the case, for example, for firms in traditional
ndustries not significantly affected by technological revolu-
ions or new market preferences. Environmental uncertainty is
educed because results and demand are reasonably foreseeable.
n such circumstances the actors tend to behave in accordance
ith a more deterministic view of the environment. The strategy
rescribed is one of adapting the organization to environmental
hreats.
Technological progress can often be seen as deriving from
he competition among technology regimes, design configura-
ions or different options for a design common to a large number
f firms. Mastery of a technology may produce irreversibilities
nd constraints: as the technology evolves, future developments
ay be tied to a particular paradigm (Dosi, 1982). New techno-
ogical discontinuities usually come from outside the paradigm,
rom a different industry, or from a new current of knowledge
Utterback, 1994).
According to Bignetti (2001), from the traditional perspec-
ive technology management has so far evolved through five
enerations, from traditional models of technology-push and
arket-pull in the 1950s and 1960s to the integrated systems
f the 1990s (Rothwell, 1993, cited by Bignetti, 2001). While
arkets, customers and suppliers were gradually inserted into
tudies as these generations developed, they are still consid-
red external sources of information for a fundamentally internal
rocess of R&D.
Technological competition is described as the result of a
ecision-making and social interaction process from which a
echnology – not necessarily the best – emerges victorious
Arthur, 1996). Contrary to expectations based on survival of
he fittest, the final solution may often be an instance of survival
f the boldest. The innovation process is seen not as a sequen-
ial process, from basic research to market, but as a spiral in
hich the development of technology is inherently tied to the
mplementation stage.
In the sphere of public health it is vital to define a clear and
onsistent strategy for action geared to meeting priority health
eeds for the different regions and population strata. Technology
s an ancillary instrument in implementing such strategies. There
re various prerequisites for adequate technology use. One of
hem, which is the focus for this paper, is to identify priorityistração e Inovação 13 (2016) 199–210 201
echnology needs so that it is possible to evaluate how far the
xisting R&D project portfolio meets those needs.
ethods  of  project  portfolio  evaluation
Project selection is one of the various aspects of R&D project
ortfolio management. In this matter, there are many differ-
nt methods that could be used for deciding which is the best
esearch portfolio. Many of these tools have been based on
uzzy sets (Pérez, Caballero, Carazo, Gómez, & Liern, 2015)
r complex methods based heavily on data and analysis, using
echniques such as the analytic hierarchy process or linear pro-
ramming (Parvaneh & El-Sayegh, 2016). Recent studies have,
owever, challenged researchers to offer methods that adapt to
ifferent types of companies and the problems they face (de
liveira Filho, Silveira, & Ana, 2014). Also, they point to the
mportance of considering other variables beyond the financial
spects, such as sustainability (Brook & Pagnanelli, 2014).
An analysis of the types of R&D project portfolio selection
ools showed four main categories, that we describe as follows.
) Risk evaluation
This type of method is based on decision trees and other
financial methodologies to evaluate the tradeoff between
risk and return, considering the R&D portfolio. Accord-
ing to Brook and Brewster (1999), developing and using a
Customer Needs Tree is a simple and effective way of solv-
ing the problem, with specific benefits in idea generation,
technology assessment, portfolio management and internal
communication.
) Portfolio grid
The portfolio grid distributes R&D projects according to
their probability of technical success and potential commer-
cial value given success. Matheson and Menke (1994) adopt
this approach, and classify projects in quadrants: bread and
butter (projects with low technical difficulty and low market-
ing potential), white elephant (projects with high technical
difficulty and low marketing potential), Oister (projects with
high technical difficulty and high marketing potential) and
pearl (projects with high potential for commercialization and
low technical difficulty). Jolly (2002) also developed a model
comprising two basic variables: technological competitive-
ness and technological attractiveness. Each can be measured
by 16 factors.
) Mixed methods
It is common to adopt mixed methods, e.g., the ones based
on financial analysis, that also classify projects on the port-
folio matrix. Tritle, Scriven, and Fusfeld (2000) adopt a
periodical review of the existing projects, followed by project
portfolio graphs, metrics and decision trees.
) Value added systems
Some authors use a more targeted approach to customer
needs than the previously shown methods. In private insti-
tutions, this may be related to the potential market for the
product. In government institutions, the system lists the best
projects through its potential contribution to society. Linton,
Walsh, and Morabito (2002) use a decision model with more
202 E.P. Vasconcellos et al. / RAI Revista de Admin
Table 1
Authors and categories of methodologies they have used.
Categories Authors
Value creation Linton et al. (2002)
Portfolio matrix Matheson and Menke (1994)
Mixed systems Tritle et al. (2000); Lint and Pennings (2001)
Trade-off risk × return Graves, Ringuest, and Case (2000); Rzasa et al.
(1990); Morris et al. (1991); Brook and Brewster
(1999); Ringuest and Graves (2005); Kolisch,
Meyer, and Mohr (2005)
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one. The authors also point that this decision is better even forource: Authors.
than one criterion, and chooses the priority projects that cre-
ate higher value for the consumer.
Table 1 synthesizes these types of methods for evaluation of
&D projects as explained before.
Following the last approach in Table 1– trade-off risk ×  return
 Osawa and Murakami (2002) developed and applied a two-
tage methodology for evaluating R&D projects in industry. The
rst stage comprises the development of the evaluation platform
n three steps:
) Philosophy: Identifies what lies behind the decision, based on
information from the firm’s business plan, strategies, vision
and mission. Two types of criteria are defined: qualitative
criteria to evaluate the suitability of a project in terms of the
extent to which it matches the firm’s strategy; and quantitative
criteria relating to financial aspects, among others.
) Outline of five criteria: (1) strategic importance and tech-
nological effect; (2) probability of realization; (3) sales; (4)
profit and (5) R&D efficiency.
) Outline of evaluation platform, comprising an analysis of
three factors: Input, calculation, and output.
The second stage deals with utilization of the evaluation plat-
orm, as summarized in Fig. 1.
Chien (2002) presents a framework for evaluating alternative
ortfolios of R&D projects. The basis for his study is the need
o evaluate inter-relations among projects. A set of very good
rojects is not necessarily best for the firm because relations
r
t
h
Input data to
evaluation
platform
Discuss
within each
laboratory
Budget planning of R
Step 2Step 1
Fig. 1. New methodology usi
Source: Osawa and Mistração e Inovação 13 (2016) 199–210
mong projects entail additional synergies not considered by
he traditional method.
Evaluation of a portfolio of R&D projects should take account
f technology needs. Technology needs identification should
ake place simultaneously along two main avenues. The first
nvolves evaluating the production processes used for a product
r service, and detecting any potential for enhancements that
ould give rise to research projects (Vasconcellos, 1990). The
econd consists of evaluating the scientific and technological
rends that could completely eliminate a disease or drastically
lter production techniques, such as the advances derived from
olecular biology and genetic engineering. S-shaped curves
nd the concepts of disruptive technologies and technological
bsolescence are discussed in depth by Sanderson and Uzumeri
1997), Christensen (1997), and Sahal (1991). Although this
aper focuses on the first avenue outlined above, any technology
eeds identification process should include both avenues.
ecommendations  for  the  evaluation  of  R&D  portfolios
Considering the recommendations and best practices to the
valuation of R&D portfolio, to Hodder and Riggs (1985), the
hoice of R&D projects requires consideration of the risk of three
istinct project phases: research, product development and sales.
atheson and Menke (1994) complement this advice with the
dea that the selection should not focus on evaluation of the indi-
idual projects; to maximize one’s return, there is need to make
uality decisions at the portfolio level mixing high risk – high
otential R&D with lower-risk projects that produce near-term
eturns through incremental improvements to existing products
nd processes.
Morris, Teisberg, and Kolbe (1991) criticize the use of
ethodologies based on the analysis of risk and return only. For
hem, this type of methodology can lead the manager to avoid
ealing with the riskier projects. However, they understand that
f two projects have the same expected payoffs and the same
osts, but different risks, and different ranges of possible out-
omes, a conscientious R&D manager should choose the riskierisk-averse managers. If a manager can choose several projects,
han he can benefit from having a portfolio of risk projects. This
appens because a project with more downsized risk has a higher
Discussion
between lab &
corporate dev.
dept.
 Mod ify
input t o
evaluation
platform
Evaluation
results posted
on intranet
&D group
Step 3 Step 4
ng evaluation platform.
urakami (2002).
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xpected value in the commercial phase and this higher value
utweighs the lower chance of success in the research phase.
Cooper, Edgett, and Kleinschmidt (1998) present the results
f a survey in which financial methods were rated as having more
eaknesses than strengths. For them, a good project follows
ix criteria: portfolios are aligned with the business objectives,
ontains very-high-value projects, reflect the business strategy,
re done on time – no gridlock, have good balance of projects
nd finally they have the right number of projects.
Tritle et al. (2000) consider that the R&D portfolio must
e in balance with corporate goals and strategies – neverthe-
ess, assessment of qualitative information is critical. Kirchhoff,
erges, and Morabito (2001) also consider, based on their expe-
ience on Lucent Technologies Lab, that the value creation is
etter than focusing only on financial aspects.
Finally, Rzasa, Faulkner, and Sousa (1990) suggest that it is
mportant to internalize the methodology at the group level and
hen internalize it at the business unit level.
In this study, we present a framework for R&D project eval-
ation that was not based on fuzzy sets, but instead considers
he specific demands for a non-governmental agency.
ethods
As seen before, this study’s objective is to present and analyze
he case of Butanta Institute and its methodology for choosing
he best portfolio of R&D when it comes to the development of
ne of its products: the Onco BCG vaccine.
This study presents the results of a practitioner work devel-
ped in Butanta Institute. Therefore, this paper is the result of
n action research methodology.
To achieve this goal, the practitioner project was developed
n 6 steps, described as follows.
) First block of interviews: First, those responsible for the
Butanta Institute, in order to collect information about the
strategic direction of the organization were interviewed. This
first block lasted for interviewing 4 h.
) Second block of interviews: In sequence, respondents were
mainly responsible for the BCG Onco product. This second
set of interviews lasted 30 h and was conducted over several
sessions. The purpose of interviews was with much depth
to determine what are the surveys that were proposed to the
institute and that would be viable for achievement. Thus, the
aim of delineating which initial portfolio of research which
is being treated. It is important to remember that, unlike what
happens in private institutions, which often need to make use
of creativity techniques to raise ideas for research to be con-
ducted in the case of Butanta Institute these ideas have been
proposed by researchers, presenting research projects that
may or may not be funded by government agencies. These
30 h of interviews were aimed at collecting information about
requests of previous studies and identify any needs that have
not been proposed by researchers to date.
) Third block of interviews: In the third block, were made with
the main panels that serve the users of BCG Onco product.
This block was designed to assess the factors critical to the
A
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success of BCG Onco from the viewpoint of its users. It
is important to note that doctors who prescribe the drug the
best people to provide information about their improvements
and critical success factors, although users of BCG Onco are
patients who are treated with this medication are. So were
collected from people dealing with doctors.
) Development of methodology to be used by the institute.
Based on the information collected, broke for the elaboration
of the method for selecting the portfolio of research at the
institute. This method is described as follows, between the
results obtained.
) Application of the methodology for selecting the portfolio
of research and data analysis. In this fifth step, we applied
this methodology to the case of BCG Onco and sought to
identify the research that have high potential alignment with
the strategy of the institute and improvements to BCG Onco
product based on the critical success factors raised in the
third step.
) Assessment methodology: The end of the application of the
methodology, were conducted more interviews with those
responsible for the BCG Onco order to verify the applicabil-
ity of the methodology used.
utanta  Institute
Butanta Institute was founded in February 1901 to combat an
utbreak of bubonic fever in the port city of Santos, in Brazil,
nd it has since become a center for research and production of
ntivenom sera. The institute currently focuses on the develop-
ent of high social impact biopharmaceuticals:
 Erythropoietin: Erythropoietin cloning and purification are
under development by the institute for use by more than
25,000 kidney patients who are awaiting transplants and cur-
rently cost the health system some 50 million US dollars.
 Lung surfactant: An industrial plant is under development for
production of 500,000 doses of lung surfactant per year, to be
used primarily in premature babies with immature lung syn-
drome due to insufficient time in the womb for lung formation.
Another application is in adult patients with lung problems.
 Anti-CD3: Anti-CD3 is under production to meet interna-
tional demand as well as for distribution in the domestic
market. It is used to constrain thrombus progression and as a
topical anticoagulant.
In recent years Butanta Institute has stood out as the lead-
ng research institution in Sao Paulo State based on the number
f indexed publications, similar to that of the main institutions
elonging to the University of Sao Paulo, with which it collabo-
ates in graduate programs for master’s and doctoral degrees in
iology and biotechnology.pplication  of  portfolio  evaluation  method
The method proposed in this paper for evaluating a portfolio
f R&D projects comprises five stages, as shown in Fig. 2.
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Strategic guidelines
Design of the evaluation matrix
• Identification and weighting of performance factors
• Study of production process and identification of production stages
Product selection
Completion of matrix
• Performance factors vs. stage of production
• Identification of technolgy needs covered by projects in progress
Proposals of new projects
• Technology gaps 
• Technology trends
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As shown in Fig. 2, the method was applied to a single prod-
ct in order to test the procedure. Thus only portfolio projects
elating to the selected product were evaluated. The procedure
hould be applied to all products of Butanta Institute, generating
 large number of projects for selection using existing methods.
roject interdependency should be taken into consideration dur-
ng this stage (Oullet & Martel, 1995; Ringuest, Graves, & Case,
999).
The analysis of the project portfolio for Onco BCG comprised
he steps set out as follows, in accordance with the stages of the
roposed methodology.
trategic  guidelines
A meeting with the Technical Committee enabled the main
trategic guidelines of Butanta Institute to be identified. We also
dentified its main areas of activity and the segments of the
ommunity served by the institute.
roduct  selection
The next step involved an initial meeting with the institute’s
oordinators followed by meetings with those responsible for
he potential products to be used in the study, as identified in
he previous step. It was then possible to decide which product
ould be studied, taking into consideration factors such as the
•lio evaluation and improvement.
te, research data.
elevance of the product to the overall strategy of the institute.
he product chosen in this case was BCG immunotherapy, also
nown as Onco BCG, currently used in the treatment of bladder
ancer.
esign  of  evaluation  matrix
This stage comprised two parts: identification and weighting
f performance factors, and study of the production process to
dentify production stages.
Identiﬁcation  and  weighting  of  performance  factors: This
tep consisted of meetings with those responsible for manufac-
uring the chosen product to determine the performance factors
ustomers expect from the product and the relative weight of
ach factor. These performance factors can be understood as
ey features to ensure that the customer’s problem is resolved
ith quality and at low cost. Customers are defined not only
s patients who receive the products for treatment but also as
hysicians who prescribe it and professionals responsible for
pplication, such as nurses and once again physicians.
Performance factors for Onco BCG are as follows: Longer  shelf  life  – The longer the shelf life, the longer the
product can be stored, meaning less waste and better control
by the nurses and physicians who use it. In addition, a product
that can be stored longer is more easily distributed to distant
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Table 2
Matrix correlating information on production stages and performance factors.
Performance factors Production stages
Priority Inputs Innoculum preparation
Culture
medium
Lyophilization
stabilizers
Glass vials
and synthetic
rubbers
Dilutant BCG
growth
Transfer to
Erlenmeyer
Culture
selection
Bacterial
film
filtration
Minimization
of cell
aggregates
Deep
fermentation
Longer shelf life A 2 1
Lower cost B 3 2 3
Less side effects B 1 1
Immunogenicity A 3 3 2 2 1 1 3
Ease of application B 1 2
Resistance to
temperature
variation
A 3 3
Performance factors Production stages
Formulation
of product
Filling Lyophilization Quality testing Storage at
institute
Transportation Storage at
application sitepH
measurement
Colony
forming units
(CFU)
Oxygen
takeup
Heat
stabil-
ity
Residual
moisture
Reconstitution
of product
Other
Longer shelf life 3 1 1 1 2 2 2
Lower cost 2 3 3 3 1 2 3 1
Less side effects 1
Immunogenicity 1 3 2 1
Ease of application 1 1
Resistance to
temperature
variation
3 1 2 2
Source: Research data.
1 = low potential impact; 2 = medium potential impact; 3 = high potential impact.
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Table 3
Performance factors and production stages for each project.
Performance factor Production stage
• Longer shelf life • Lyophilization stabilizers
• Lyophilization
• Colony-forming units (CFU)
• Oxygen takeup
• Heat stability
• Lower cost • Lyophilization stabilizers
• Lyophilization
• Colony-forming units (CFU)
• Oxygen takeup
• Heat stability
• Resistance to temperature variation • Lyophilization
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regions or locations that use it on a smaller scale. The latter
can receive annual shipments of the product, for example.
 Lower  cost  – Lower cost allows for production of larger quan-
tities and thus coverage of an even larger segment of the
population in need of the product.
 Less  side  effects  – Side effects are undesirable consequences
of treatment with medication. Less side effects mean better
quality treatment and more patient satisfaction.
 Immunogenicity  – Immunogenicity is the patient’s response
to the medication. A high degree of immunogenicity indi-
cates that the product is doing its job and that treatment is
proceeding satisfactorily.
 Ease  of  application  – The product should be easy and conve-
nient to apply. This means, for example, rapid reconstitution
and no need for an arsenal of equipment for administering the
product.
 Resistance  to  temperature  variation  – The medication needs
to be stored, transported and handled under differing condi-
tions in terms of temperature and the general environment.
It should be formulated and packaged in such a way as to
withstand temperature variations and to suit the environment
in which it will be used.
tudy  of  production  process  and  identiﬁcation  of  production
tages
Once the performance factors had been determined, the Onco
CG production process was mapped out. More meetings were
eld to discuss details of the production process, divide it into
tages, and diagnose each stage separately. This step of the
ethodology included a visit to the production facility, provid-
ng an opportunity to see how Onco BCG is manufactured and
n particular the rigorous care taken at every stage of the pro-
ess. The columns in Chart 4-1 represent the various stages of
roduction.
ompletion  of  matrix
The matrix produced in the previous step was completed
n two stages: performance factors vs. stages of production;
nd identification of technology needs covered by projects in
rogress.
Performance  factors  vs.  stages  of  production: To facilitate the
nalysis and as part of the proposed methodology, a matrix was
reated (Table 2) correlating the information on performance
actors and production stages. Each cell in which the two vari-
bles intersect is used to show the importance of each production
tage in achieving the performance factors for the end-product.
Each cell is ranked on a scale from 1 to 3. Cells with the
ighest potential to have a positive influence on the desired per-
ormance are ranked 3. Cells with little or no importance in
erms of potential satisfaction of the performance criteria are
eft blank.As shown in Table 2, identification of technology needs cov-
red by projects in progress: the matrix presented above was
ompleted in order to analyze the research projects in progress
t the institute and measure their relevance. Relevance is
n
o
P
p• Heat stability
ource: Research data.
epresented in terms of the contribution of each production
tage to achievement of the performance factors defined for the
roject. Thus by correlating performance factors with the cor-
esponding stages of production it is possible to relate projects
n progress with the product’s performance requirements. It is
mportant to note that needs identification is necessary but not
ufficient. Scientists tend to resist demands not directly related
o their specialties. A study by Cohen, Duberley, and Mcauley
1999) involving seven government-funded research institutions
nalyzed their need for outsourced research and the impact on
he scientists working there, showing the significance of motiva-
ion to ensure that part of the work done by research institutions
s geared to meeting society’s needs.
For each project a detailed chart similar to the example in
able 3 was prepared, showing the production stages involved
n the project and the performance factors relating to each stage.
he charts were used to guide completion of the matrix presented
n item 4.7 as follows.
xample:  Project  1  (P1)  – production  of  freeze-dried  BCG
accine  by  sealing  under  argon
Objective: Implement the use of argon 5.0 (99.999% purity)
or lyophilizer vacuum breaks after bulk lyophilization of BCG
accine, thus assuring maximum product stability and rigorous
ontrol of residual moisture.
roposals  for  new  projects
This step of the methodology has two phases – technology
aps and technology trends.
Technology  gaps: This phase of the study is designed to
nalyze the matrix completed in the preceding step, identify
echnology needs not covered by the existing project portfolio,
nd generate new project proposals.
Table 4 which is based on the matrix presented in Table 3,
hows the analysis performed to determine new technology
eeds. Projects already in progress at the time this methodol-
gy was introduced are represented by numbers (P1, P2, . .  .,
n). Inclusion of an asterisk (P*1, P*2, . .  ., P*n) indicates
rojects created in accordance with needs identified using the
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Table 4
Projects covering each correlation of production stages and performance factors.
Performance factors Production stages
Priority Inputs Innoculum preparation
Culture
medium
Lyophilization
stabilizers
Glass vials
and synthetic
rubbers
Dilutant BCG
growth
Transfer to
Erlenmeyer
Culture
selection
Bacterial
film
filtration
Minimization
of cell
aggregates
Deep
fermentation
Longer shelf life A 2
P1
P*2
P*5
1
P*5
Lower cost B 3
P*2
P*4
P*5
2
P1
P5
P*2
P*5
P*6
3

P*2
P*4
P*5
Less side effects B 1
P5
P*1
P*2
P*5
1
P*2
P*4
P*5
P*6
Immunogenicity A 3
P5
P*1
P*2
P*4
P*5
3
P5
P*1
P*2
P*4
2
P5
P*1
P*2
P*4
2
P5
P*1
P*2
P*4
1
P5
P*1
P*2
P*4
1

P*2
P*4
P*5
3

P*2
P*4
Ease of application B 1
P*5
2
P*5
P*6
Resistance to
temperature
variation
A 3
P5
P*2
3
P*2
P*5
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Table 4 (Continued)
Performance factors Production stages
Formulation
of product
Filling Lyophilization Quality testing Storage at
institute
Transportation Storage at
application sitepH
measurement
Colony
forming units
(CFU)
Oxygen
takeup
Heat
stability
Residual
moisture
Reconstitution
of product
Other
Longer shelf life 3
P1
P*2
P*5
1
P1
P5
P*2
P*4
P*5
1
P1
P5
P*2
P*4
P*5
1
P1
P*2
P*5
2

2

2

P*8
P*10
Lower cost 2
P1
P2
P*2
P*5
P*6
3
P1
P4
P5
P*2
P*3
P*4
P*5
P*6
3
P1
P3
P4
P5
P*2
P*3
P*4
P*5
P*6
3
P1
P*2
P*5
P*6
1
P*6
2

3

P*7
2

P*8
P*9
P*11
Less side effects 1

Immunogenicity 1

P*2
P*5
P*6
3
P5
P*1
P*2
P*4
2
P6
P7
1

P*10
Ease of application 1
P*5
P*6
1

Resistance to
temperature
variation
3
P1
P*2
P*5
P*6
1
P1
P*2
P*5
P*6
2

P*7
2

P*7
P*9
 = needs not covered by any project in progress; Pn = project in progress n; P*n  = new project *n.
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ethodology. Triangles highlight significant correlations not
overed by existing research and development projects. If the
ethodology was applied in its complete form, databases on
rojects in progress at the various research institutions linked to
utanta Institute would also be queried.
Technology trends: The analysis performed to date needs to
e supplemented by a second avenue of approach focusing on
he trends in technology and science that could make the current
roduction process used in manufacturing Onco BCG totally
bsolete or unnecessary, owing for example to the introduction
f other treatments that completely cure the diseases treated by
nco BCG. Examples of such trends in the case of Onco BCG
nclude:
 Research on recombinant BCG, using molecular biology to
express proteins from other microorganisms that induce an
immune response and afford protection against various dis-
eases.
 Research on recombinant BCG with altered production of
mycobacterial proteins, which could be tested in the treatment
of bladder cancer.
 Research on recombinant BCG producing proteins that mod-
ulate the immune system in cancer treatment.
 Research on fermentation routes to substitute cultivation in
glass vials.
losing  remarks
This study aimed to develop and present a methodology for
electing the portfolio of research and development (R&D). The
ethodology presented was developed within the Butanta Insti-
ute, one connected with the Health Department of the State of
ao Paulo organization.
First, we sought to analyze the literature on the selection of
esearch projects and development. The literature review showed
hat the authors address this question from four major perspec-
ives. The first is composed of items that leave the concept of
reating value to determine what the best investments in research
nd development. A second category of articles is worth the
ortfolio matrix techniques, we classify queries that may be
eveloped along two axes of the matrix. There is also, in a
hird category, mixed systems, which draw on the concept of
alue creation and portfolio matrices. However, it is a signifi-
ant number of authors in the fourth category – methods that
se the concepts of risk and return for selecting the portfolio of
esearch to be developed.
The method shown in this paper has some peculiarities in
egard to previous studies. Much of the literature on R&D eval-
ation is based on complex mathematical tools and focuses on
nancial aspects, characteristics that are not appropriate for non-
rofit organizations (Schaeffer & Cruz-Reyes, 2016) – which is
he case of Instituto Butanta. To adapt to this kind of organiza-
ion, the proposed method has two main characteristics.First, it considers the opinion of the group who is responsi-
le for taking decisions. This has been previously pointed by
ee and Kim (2000) as necessary when the projects evaluated
ave possible impacts for society. Additionally, as in the case of
B
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nstituto Butanta, when projects are managed by a group of indi-
iduals, it is necessary to consider the group members’ opinions
hen deciding which project to invest.
Second, it takes into account the opinions of experts when
udging the potential value of the projects. According to Liu,
ang, Ma, and Sun (2016), it is more adequate than financial
easures when the projects’ potential gains are not necessarily
onetary, but instead subjective or parts of larger technological
iscoveries.
This analysis of the literature showed that most of the theo-
ies that apply to private organizations can be applied in public
rganizations, in particular as regards the issue of improvements
n health. However, the concepts of risk and return, when treated
rom a financial perspective, become not ideal tools for this sit-
ation, since the investments in research in the area of health are
ften risky, and managers cannot judge the best investment for
hose who bring minor scratches. For example, riskier research
an often those related to large and significant improvements,
uch as curing major diseases.
Based on this literature, we developed and applied a method-
logy for the selection of research at the Butanta Institute. It was
ased on a substantial number of hours of interviews to obtain
ata that provided the basis for the study.
The results showed, first, that the selection of the portfolio
f research should first be based on the strategic direction of
he institution. Another assumption that is made is based on
ustomers’ perceptions of the product studied – the BCG Onco
 about which requirements should be prioritized when it sought
o improve the product – what are the critical success factors.
The methodology and its evaluation by the responsible in the
utanta Institute, showed that this method was easy to apply and
se, may be used by the institution for the selection of research
o be conducted.
Based on the results, we conclude that, although the tech-
iques are based on risk and financial return are of higher value,
esearchers and R&D managers must consider the strategic and
lient perspectives when selecting the best portfolio of research.
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